You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 352 Target modulation within the tumor microenvironment (TME) by daratumumab (anti-CD38) but not edicotinib (CSF-1R inhibitor) in men with high-risk localized prostate cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials Completed
352 Target modulation within the tumor microenvironment (TME) by daratumumab (anti-CD38) but not edicotinib (CSF-1R inhibitor) in men with high-risk localized prostate cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to August 2024

AbstractFullPdf
Nov 2021215011
Dec 20216003
Jan 20224402
Feb 20224805
Mar 202220003
Apr 20225605
May 20223209
Jun 20221403
Jul 20221401
Aug 20223803
Sep 20222205
Oct 20221804
Nov 20221804
Dec 20221600
Jan 20232606
Feb 20233002
Mar 20232201
Apr 2023601
May 2023802
Jun 2023603
Jul 2023805
Aug 20231801
Sep 20231001
Oct 2023600
Nov 20232003
Dec 20232802
Jan 20242804
Feb 20242802
Mar 20242203
Apr 20242202
May 20241601
Jun 2024400
Jul 20241604
Aug 2024802
Total11270103